{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:29:52Z","timestamp":1773271792461,"version":"3.50.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1097\/mpa.0b013e31821f66b4","type":"journal-article","created":{"date-parts":[[2011,6,23]],"date-time":"2011-06-23T11:31:50Z","timestamp":1308828710000},"page":"987-994","source":"Crossref","is-referenced-by-count":37,"title":["Evaluating the Characteristics and the Management of Patients With Neuroendocrine Tumors Receiving Octreotide LAR During a 6-Year Period"],"prefix":"10.1097","volume":"40","author":[{"given":"Lowell","family":"Anthony","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron I.","family":"Vinik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210212","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1210\/er.2003-0014","article-title":"The diagnosis and medical management of advanced neuroendocrine tumors.","volume":"25","author":"Kaltsas","year":"2004","journal-title":"Endocr Rev"},{"key":"R2-1-20210212","first-page":"429","article-title":"Carcinoid tumors.","volume":"74","author":"Robertson","year":"2006","journal-title":"Am Fam Physician"},{"key":"R3-1-20210212","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"R4-1-20210212","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2214\/ajr.182.3.1820559","article-title":"Carcinoid tumors of the small bowel: a multitechnique imaging approach.","volume":"182","author":"Horton","year":"2004","journal-title":"AJR Am J Roentgenol"},{"key":"R5-1-20210212","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1590\/S0004-27302005000500028","article-title":"Carcinoid syndrome: diagnosis and medical management.","volume":"49","author":"van der Lely","year":"2005","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"R6-1-20210212","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1200\/JCO.2006.10.1535","article-title":"Chromogranin A: is it a useful marker of neuroendocrine tumors?","volume":"25","author":"Campana","year":"2007","journal-title":"J Clin Oncol"},{"key":"R8-1-20210212","doi-asserted-by":"crossref","first-page":"502","DOI":"10.4065\/80.4.502","article-title":"Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors.","volume":"80","author":"Delaunoit","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"R9-1-20210212","first-page":"942","article-title":"Metastasizing carcinoid of the small intestine, tricuspid valve disease and pulmonary stenosis, a new syndrome in German.","volume":"84","author":"Hedinger","year":"1954","journal-title":"Schweiz Med Wochenschr"},{"key":"R10-1-20210212","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0024-3205(82)90087-X","article-title":"SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.","volume":"31","author":"Bauer","year":"1982","journal-title":"Life Sci"},{"key":"R11-1-20210212","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.cgh.2005.12.008","article-title":"Therapeutic options for gastrointestinal carcinoids.","volume":"4","author":"Modlin","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R12-1-20210212","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.11105","article-title":"A 5-decade analysis of 13,715 carcinoid tumors.","volume":"97","author":"Modlin","year":"2003","journal-title":"Cancer"},{"key":"R13-1-20210212","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/MPA.0b013e3181db01a8","article-title":"A prospective trial on the effect of body mass index and sex on plasma octreotide levels in patients undergoing long-term octreotide LAR therapy.","volume":"39","author":"Joseph","year":"2010","journal-title":"Pancreas"},{"key":"R14-1-20210212","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/er.2000-0001","article-title":"The pathophysiological consequences of somatostatin receptor internalization and resistance.","volume":"24","author":"Hofland","year":"2003","journal-title":"Endocr Rev"},{"issue":"suppl 1","key":"R15-1-20210212","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000080737","article-title":"Complications of midgut carcinoid tumors and carcinoid syndrome.","volume":"80","author":"Van der Horst-Schrivers AN, Wymenga","year":"2004","journal-title":"Neuroendocrinology"},{"key":"R16-1-20210212","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/cncr.11226","article-title":"Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor.","volume":"97","author":"Zuetenhorst","year":"2003","journal-title":"Cancer"},{"key":"R17-1-20210212","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1038\/sj.bjc.6601816","article-title":"Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease.","volume":"90","author":"Zuetenhorst","year":"2004","journal-title":"Br J Cancer"},{"key":"R18-1-20210212","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1161\/01.CIR.77.2.264","article-title":"Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities.","volume":"77","author":"Lundin","year":"1988","journal-title":"Circulation"},{"key":"R19-1-20210212","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1161\/01.CIR.66.5.1059","article-title":"Carcinoid heart disease: diagnosis by two-dimensional echocardiography.","volume":"66","author":"Howard","year":"1982","journal-title":"Circulation"},{"key":"R20-1-20210212","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/hrt.64.3.190","article-title":"Transoesophageal echocardiography improves the diagnostic value of cardiac ultrasound in patients with carcinoid heart disease.","volume":"64","author":"Lundin","year":"1990","journal-title":"Br Heart J"},{"key":"R21-1-20210212","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/01.CIR.92.4.790","article-title":"Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography.","volume":"92","author":"Robiolio","year":"1995","journal-title":"Circulation"},{"key":"R22-1-20210212","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.","volume":"17","author":"Rubin","year":"1999","journal-title":"J Clin Oncol"},{"key":"R23-1-20210212","first-page":"8","article-title":"Hypertension awareness, treatment, and control-continued disparities in adults: United States, 2005-2006.","volume":"1-","author":"Ostchega","year":"2008","journal-title":"NCHS Data Brief"},{"key":"R24-1-20210212","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1196\/annals.1353.007","article-title":"Catecholamine-secreting metastatic carcinoid as differential diagnosis in pheochromocytoma: clinical, laboratory, and imaging clues in the search for the lurking neuroendocrine tumor (NET).","volume":"1073","author":"Whitman","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"R25-1-20210212","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1161\/01.HYP.26.1.213","article-title":"Chromogranin A in human hypertension. Influence of heredity.","volume":"26","author":"Takiyyuddin","year":"1995","journal-title":"Hypertension"},{"key":"R26-1-20210212","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1463-1326.2006.00575.x","article-title":"Catecholamine storage vesicles and the metabolic syndrome: the role of the chromogranin A fragment pancreastatin.","volume":"8","author":"Zhang","year":"2006","journal-title":"Diabetes Obes Metab"},{"key":"R28-1-20210212","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours.","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol"},{"key":"R30-1-20210212","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group.","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"R31-1-20210212","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/MPA.0b013e3181ea5839","article-title":"Neuroendocrine tumors: a critical appraisal of management strategies.","volume":"39","author":"Vinik","year":"2010","journal-title":"Pancreas"},{"key":"R32-1-20210212","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","article-title":"Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.","volume":"28","author":"Yao","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00006676-201110000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:11:34Z","timestamp":1618035094000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006676-201110000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/mpa.0b013e31821f66b4","relation":{},"ISSN":["0885-3177"],"issn-type":[{"value":"0885-3177","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}